Herein, we explored the utility of PRL3-zumab in treating HCC, a disease with frequent PRL3 overexpression18,19, and with an unmet need for efficacious and well-tolerated targeted drugs20. This evidence concerns the gene PTP4A3 and hepatocellular carcinoma.